Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Newcastle Melanoma Unit (NMU) is a premier clinical and research center based in Newcastle, Australia, specializing in the multidisciplinary management of melanoma and complex skin cancers. Established in 1981, the unit integrates advanced surgical oncology, specialized dermatology, and a robust clinical trials program to provide comprehensive patient care. NMU is internationally recognized for its significant contributions to the development of modern immunotherapies and targeted treatments, frequently serving as a high-volume site for global Phase 2 and Phase 3 clinical trials. Affiliated with the Melanoma Institute Australia and located within the Calvary Mater Newcastle hospital, the unit serves as a critical tertiary referral hub for the Hunter New England region. Its expertise encompasses the entire patient journey, from early-stage diagnosis and surgical intervention to the management of advanced metastatic disease through innovative systemic therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Newcastle Melanoma Unit.